Inhibrx Biosciences, Inc.
INBXDrugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 12, 2026
7dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
INBX Earnings Report
EPS Est: $-2.50 | FQ end 2026-06
INBRX-106
Head and Neck Squamous Cell Carcinoma (HNSCC)
INBRX-109
Conventional Chondrosarcoma
INBRX-106 - Hexavalent OX40 agonist antibody
Solid Tumor
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
INBRX-106 | Phase 3 | Head and Neck Squamous Cell Carcinoma (HNSCC) | - | - |
INBRX-109 | Phase 2 | Conventional Chondrosarcoma | - | - |
INBRX-106 - Hexavalent OX40 agonist antibody | Phase 2 | Solid Tumor | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Inhibrx Biosciences, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Inhibrx Biosciences, Inc.'s (INBX) pipeline across Phase 3, Phase 2. Its lead program is INBRX-106 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Inhibrx Biosciences, Inc.'s next FDA catalyst?→
Inhibrx Biosciences, Inc.'s (INBX) next tracked catalyst is a Earnings expected August 12, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track INBX biotech catalysts?→
Add INBX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Inhibrx Biosciences, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.